Associated Papers
PharmVar GeneFocus: CYP2A6.
Langlois AWR et al.
Clinical Pharmacology and Therapeutics, 2024
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.
Muñiz P et al.
Frontiers in Immunology, 2022
36211438 (PubMed )
Supplement: Table_1.xlsx › Hoja1
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › M121224
CYP2A6 Longitudinal Effects in Young Smokers.
Cannon DS et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 2016
The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Bloom J et al.
Pharmacogenetics and Genomics, 2011
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
Gresner P et al.
Lung Cancer (amsterdam, Netherlands), 2007
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M et al.
Pharmacogenetics and Genomics, 2005
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T et al.
Clinical Pharmacology and Therapeutics, 2004
Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).
von Richter O et al.
Pharmacogenetics, 2004
A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.
Pitarque M et al.
Human Mutation, 2004
Select a paper to view details